MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-04-2026
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
105 M |
Market Cap[1] |
$ 81.6 B |
EBITDA (LTM) |
$ 4.1 B |
P/E (LTM) |
16.73 |
P/S (LTM) |
5.82 |
EPS (LTM) |
46.47 |
Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.
Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.
One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.
The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 80.34 | -1.83 % | $ 1.55 B | Nasdaq Global Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 0.84 | 3.54 % | $ 4.58 M | Nasdaq Global Select Market |  China |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Adagene
ADAG
|
$ 2.67 | 1.52 % | $ 150 M | Nasdaq Global Market | China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.57 | 1.13 % | $ 8.59 B | Nasdaq Capital Market |  Australia |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 110.34 | 3.49 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 2.44 | -2.79 % | $ 2.85 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 4.22 | 1.44 % | $ 9.18 B | NYSE American |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 1.5 | 7.91 % | $ 281 M | Nasdaq Global Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 222.03 | -0.05 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.71 | 2.4 % | $ 153 M | Nasdaq Global Market,SPB | Israel |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 8.97 | 0.56 % | $ 1.43 B | NYSE | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 41.31 | 1.18 % | $ 4.26 B | Nasdaq Capital Market,SPB | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.45 | 0.04 % | $ 2.9 B | Nasdaq Capital Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.58 | -1.25 % | $ 75.3 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.7 | 1.97 % | $ 4.19 B | Nasdaq Global Market,SPB |  Schweiz |
|
Champions Oncology
CSBR
|
$ 6.55 | - | $ 89.5 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.46 | 2.82 % | $ 373 M | Nasdaq Global Select Market | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
$ 14.52 | - | $ 4.49 B | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.